Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.38 +2.6%	$1.98	$0.95 ▼ $2.87	$20.83M	0.13	381,366 shs	189,746 shs
MGNX MacroGenics	$1.54 +1.3%	$1.48	$0.99 ▼ $5.77	$95.90M	1.59	838,958 shs	586,353 shs
ONCY Oncolytics Biotech	$1.32 +5.6%	$0.66	$0.33 ▼ $1.53	$117.86M	1.07	735,001 shs	1.24 million shs
ZURA Zura Bio	$1.96 +51.9%	$1.17	$0.97 ▼ $5.07	$88.20M	-0.1	498,963 shs	7.79 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	+6.91%	-1.69%	+17.17%	+128.57%	-17.14%
MGNX MacroGenics	+2.01%	-4.40%	+1.33%	+20.63%	-71.77%
ONCY Oncolytics Biotech	+10.62%	+4.17%	+95.16%	+122.82%	+16.82%
ZURA Zura Bio	-0.77%	-4.44%	+7.50%	+4.88%	-66.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYTU Aytu BioPharma	4.2235 of 5 stars	3.5	4.0	3.4	3.8	0.0	0.6
MGNX MacroGenics	4.3358 of 5 stars	3.2	4.0	4.4	2.0	2.5	0.6
ONCY Oncolytics Biotech	1.5078 of 5 stars	3.4	3.0	0.0	1.5	0.0	0.0
ZURA Zura Bio	3.041 of 5 stars	3.6	3.0	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	3.00	Buy	$10.00	320.17% Upside
MGNX MacroGenics	2.40	Hold	$5.71	271.06% Upside
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	228.28% Upside
ZURA Zura Bio	3.13	Buy	$14.33	631.29% Upside

Current Analyst Ratings Breakdown

Latest AYTU, MGNX, ZURA, and ONCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	AYTU Aytu BioPharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/30/2025	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$81M	0.26	N/A	N/A	$4.64 per share	0.51
MGNX MacroGenics	$149.96M	0.65	N/A	N/A	$1.85 per share	0.83
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.05 per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	9/24/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/5/2025 (Estimated)
ONCY Oncolytics Biotech	-$23.14M	-$0.29	N/A	N/A	N/A	N/A	-313.77%	-130.19%	7/30/2025 (Estimated)
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-42.84%	-35.22%	8/12/2025 (Estimated)

Latest AYTU, MGNX, ZURA, and ONCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ZURA Zura Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ONCY Oncolytics Biotech	-$0.10	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	MGNX MacroGenics	-$0.59	N/A	N/A	N/A	$28.06 million	N/A
5/14/2025	Q3 2025	AYTU Aytu BioPharma	-$0.17	$0.20	+$0.37	$0.21	$13.74 million	$18.45 million
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.03	0.87
MGNX MacroGenics	N/A	3.28	3.11
ONCY Oncolytics Biotech	N/A	3.20	3.20
ZURA Zura Bio	N/A	8.14	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
MGNX MacroGenics	96.89%
ONCY Oncolytics Biotech	6.82%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	3.60%
MGNX MacroGenics	13.00%
ONCY Oncolytics Biotech	0.10%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable
ONCY Oncolytics Biotech	30	94.28 million	94.19 million	Not Optionable
ZURA Zura Bio	3	68.38 million	58.65 million	Optionable

AYTU, MGNX, ZURA, and ONCY Headlines

Recent News About These Companies

Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Rating of "Buy" from Analysts

July 13, 2025 | americanbankingnews.com

Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by Analysts

July 13, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Stock Price Up 12.5% - Should You Buy?

July 10, 2025 | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Trading 12.5% Higher - Here's What Happened

July 10, 2025 | marketbeat.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Buy" by Analysts

June 18, 2025 | marketbeat.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.comS

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 25, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU, MGNX, ZURA, and ONCY Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.38 +0.06 (+2.59%)

Closing price 04:00 PM Eastern

Extended Trading

$2.35 -0.03 (-1.26%)

As of 06:36 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

MacroGenics NASDAQ:MGNX

$1.54 +0.02 (+1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 +0.03 (+2.27%)

As of 06:54 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Oncolytics Biotech NASDAQ:ONCY

$1.32 +0.07 (+5.60%)

Closing price 04:00 PM Eastern

Extended Trading

$1.31 -0.01 (-0.76%)

As of 07:59 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Zura Bio NASDAQ:ZURA

$1.96 +0.67 (+51.94%)

Closing price 04:00 PM Eastern

Extended Trading

$1.96 0.00 (-0.26%)

As of 07:59 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time